Phase 1 pharmacokinetic study of the oral pan-AKT inhibitor MK-2206 in Japanese patients with advanced solid tumors

被引：0
作者：
Toshihiko Doi
Kenji Tamura
Yuko Tanabe
Kan Yonemori
Takayuki Yoshino
Nozomu Fuse
Makoto Kodaira
Hideaki Bando
Kazuo Noguchi
Takashi Shimamoto
Atsushi Ohtsu
机构：
[1] National Cancer Center Hospital East,Exploratory Oncology Research & Clinical Trial Center
[2] National Cancer Center Hospital,undefined
[3] National Cancer Center,undefined
[4] MSD K.K.,undefined
来源：
Cancer Chemotherapy and Pharmacology | 2015年 / 76卷
关键词：
MK-2206; pan-AKT inhibitor; Pharmacokinetics; Phase I study; Skin toxicity;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：409 / 416
页数：7
相关论文
共 50 条
[41]   Multicenter phase II study of the AKT inhibitor MK-2206 in recurrent or metastatic nasopharyngeal carcinoma from patients in the mayo phase II consortium and the cancer therapeutics research group (MC1079) [J].
Ma, B. B. Y. ;
Goh, B. C. ;
Lim, W. T. ;
Hui, E. P. ;
Tan, E. H. ;
Lopes, G. de Lima ;
Lo, K. W. ;
Li, L. ;
Loong, H. ;
Foster, N. R. ;
Erlichman, C. ;
King, A. D. ;
Kam, M. K. M. ;
Leung, S. F. ;
Chan, K. C. ;
Chan, A. T. C. .
INVESTIGATIONAL NEW DRUGS, 2015, 33 (04) :985-991
[42]   Pre-surgical trial of the AKT inhibitor MK-2206 in patients with operable invasive breast cancer: a New York Cancer Consortium trial [J].
Kalinsky, K. ;
Sparano, J. A. ;
Zhong, X. ;
Andreopoulou, E. ;
Taback, B. ;
Wiechmann, L. ;
Feldman, S. M. ;
Ananthakrishnan, P. ;
Ahmad, A. ;
Cremers, S. ;
Sireci, A. N. ;
Cross, J. R. ;
Marks, D. K. ;
Mundi, P. ;
Connolly, E. ;
Crew, K. D. ;
Maurer, M. A. ;
Hibshoosh, H. ;
Lee, S. ;
Hershman, D. L. .
CLINICAL & TRANSLATIONAL ONCOLOGY, 2018, 20 (11) :1474-1483
[43]   Phase 1 Pharmacokinetic and Drug-Interaction Study of Dasatinib in Patients With Advanced Solid Tumors [J].
Johnson, Faye M. ;
Agrawal, Shruti ;
Burris, Howard ;
Rosen, Lee ;
Dhillon, Navneet ;
Hong, David ;
Blackwood-Chirchir, Anne ;
Luo, Feng R. ;
Sy, Oumar ;
Kaul, Sanjeev ;
Chiappori, Alberto A. .
CANCER, 2010, 116 (06) :1582-1591
[44]   Phase I Pharmacokinetic/Pharmacodynamic Study of MLN8237, an Investigational, Oral, Selective Aurora A Kinase Inhibitor, in Patients with Advanced Solid Tumors [J].
Cervantes, Andres ;
Elez, Elena ;
Roda, Desamparados ;
Ecsedy, Jeffrey ;
Macarulla, Teresa ;
Venkatakrishnan, Karthik ;
Rosello, Susana ;
Andreu, Jordi ;
Jung, JungAh ;
Sanchis-Garcia, Juan Manuel ;
Piera, Adelaida ;
Blasco, Inma ;
Manos, Laura ;
Perez-Fidalgo, Jose-Alejandro ;
Fingert, Howard ;
Baselga, Jose ;
Tabernero, Josep .
CLINICAL CANCER RESEARCH, 2012, 18 (17) :4764-4774
[45]   Pre-surgical trial of the AKT inhibitor MK-2206 in patients with operable invasive breast cancer: a New York Cancer Consortium trial [J].
K. Kalinsky ;
J. A. Sparano ;
X. Zhong ;
E. Andreopoulou ;
B. Taback ;
L. Wiechmann ;
S. M. Feldman ;
P. Ananthakrishnan ;
A. Ahmad ;
S. Cremers ;
A. N. Sireci ;
J. R. Cross ;
D. K. Marks ;
P. Mundi ;
E. Connolly ;
K. D. Crew ;
M. A. Maurer ;
H. Hibshoosh ;
S. Lee ;
D. L. Hershman .
Clinical and Translational Oncology, 2018, 20 :1474-1483
[46]   A phase I and pharmacokinetic study of elisidepsin (PM02734) in patients with advanced solid tumors [J].
Salazar, R. ;
Jones, R. J. ;
Oaknin, A. ;
Crawford, D. ;
Cuadra, C. ;
Hopkins, C. ;
Gil, M. ;
Coronado, C. ;
Soto-Matos, A. ;
Cullell-Young, M. ;
Iglesias Dios, J. L. ;
Evans, T. R. J. .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2012, 70 (05) :673-681
[47]   A phase I and pharmacokinetic study of elisidepsin (PM02734) in patients with advanced solid tumors [J].
R. Salazar ;
R. J. Jones ;
A. Oaknin ;
D. Crawford ;
C. Cuadra ;
C. Hopkins ;
M. Gil ;
C. Coronado ;
A. Soto-Matos ;
M. Cullell-Young ;
J. L. Iglesias Dios ;
T. R. J. Evans .
Cancer Chemotherapy and Pharmacology, 2012, 70 :673-681
[48]   Phase 1 study of galunisertib, a TGF-beta receptor I kinase inhibitor, in Japanese patients with advanced solid tumors [J].
Fujiwara, Yutaka ;
Nokihara, Hiroshi ;
Yamada, Yasuhide ;
Yamamoto, Noboru ;
Sunami, Kuniko ;
Utsumi, Hirofumi ;
Asou, Hiroya ;
Takahash, Osamu, I ;
Ogasawara, Ken ;
Gueorguieva, Ivelina ;
Tamura, Tomohide .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2015, 76 (06) :1143-1152
[49]   Phase 1 study of galunisertib, a TGF-beta receptor I kinase inhibitor, in Japanese patients with advanced solid tumors [J].
Yutaka Fujiwara ;
Hiroshi Nokihara ;
Yasuhide Yamada ;
Noboru Yamamoto ;
Kuniko Sunami ;
Hirofumi Utsumi ;
Hiroya Asou ;
Osamu TakahashI ;
Ken Ogasawara ;
Ivelina Gueorguieva ;
Tomohide Tamura .
Cancer Chemotherapy and Pharmacology, 2015, 76 :1143-1152
[50]   Phase I, dose escalation and pharmacokinetic study of cediranib (RECENTIN™), a highly potent and selective VEGFR signaling inhibitor, in Japanese patients with advanced solid tumors [J].
Noboru Yamamoto ;
Tomohide Tamura ;
Nobuyuki Yamamoto ;
Kazuhiko Yamada ;
Yasuhide Yamada ;
Hiroshi Nokihara ;
Yutaka Fujiwara ;
Toshiaki Takahashi ;
Haruyasu Murakami ;
Narikazu Boku ;
Kentaro Yamazaki ;
Thomas A. Puchalski ;
Eisei Shin .
Cancer Chemotherapy and Pharmacology, 2009, 64 :1165-1172
12345